Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 54

Results For "S-1"

939 News Found

Dozee partners British International Investment to transform public healthcare in India
Healthcare | January 13, 2023

Dozee partners British International Investment to transform public healthcare in India

The goal of Dozee’s partnership with BII is to improve access to healthcare across India and alleviate the workload of healthcare workers, reduce nurse burnout and fatigue in hospital wards


Zydus receives final approval and 180 days shared exclusivity from USFDA for Brexpiprazole tablets
Drug Approval | January 13, 2023

Zydus receives final approval and 180 days shared exclusivity from USFDA for Brexpiprazole tablets

Brexpiprazole is an atypical antipsychotic indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults


Zydus launches Topiramate Extended-Release Capsules
Drug Approval | January 07, 2023

Zydus launches Topiramate Extended-Release Capsules

Zydus is the first company to receive final approval and launch Topiramate Extended-Release Capsules, USP 25 mg, 50 mg, and 100 mg in the United States.


Lupin launches novel fixed-dose triple drug combination DIFIZMA DPI to treat Asthma
News | January 06, 2023

Lupin launches novel fixed-dose triple drug combination DIFIZMA DPI to treat Asthma

The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”


BDR Pharmaceutical launches the first generic to treat Prostate cancer in India
News | January 04, 2023

BDR Pharmaceutical launches the first generic to treat Prostate cancer in India

BDRs journey for the treatment of Prostate Cancer started with Abiratarone Acetate, then Leuprolide Acetate followed by Enzalutamide and, then Degarelix and Triptorelin.


Granules partners with Greenko ZeroC to enable green molecule solutions
Sustainability | January 03, 2023

Granules partners with Greenko ZeroC to enable green molecule solutions

Greenko ZeroC will supply Carbon Free Energy and enable Green Hydrogen along with its various chemical derivatives.


MoU signed for commercial production of indigenously developed vaccine ‘Lumpi-ProVac’
Policy | January 02, 2023

MoU signed for commercial production of indigenously developed vaccine ‘Lumpi-ProVac’

Lumpi-ProVacind is used for the prophylactic immunization of animals against Lumpy Skin Disease, which illicit protection for about one year


Aster DM Healthcare inks O&M agreement to operate hospital in Mandya
Healthcare | January 01, 2023

Aster DM Healthcare inks O&M agreement to operate hospital in Mandya

The term of O&M is for 15 years with a lock in period of 5 years for the Company and 15 years for VHPL & Bharathi Education trust.


USFDA accepts for review the biologics license application for Pfizer’s Investigational MenABCWY in adolescents
Drug Approval | December 31, 2022

USFDA accepts for review the biologics license application for Pfizer’s Investigational MenABCWY in adolescents

If approved, the vaccine could help simplify the meningococcal vaccination schedule and provide the broadest serogroup coverage of any meningococcal vaccine


Aurobindo's subsidiary Tergene Biotech receives SEC recommendation for pneumococcal 15 valent vaccine
Drug Approval | December 28, 2022

Aurobindo's subsidiary Tergene Biotech receives SEC recommendation for pneumococcal 15 valent vaccine

The company continue to develop this program for the WHO markets, thereby providing coverage and protection for more infants globally in time to come